FABP9 and prostate carcinoma: In addition, some studies still focus on measuring the expression levels of FABPs but have not been able to explain the valid correlation related to the tested FABP’s contribution to the discussed pathological diseases, as was the case in studies on the potential of T-FABP as a biomarker for prostate cancer [92] and I-FABP as a biomarker for acute ischemic stroke [40].